ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Lai et al. synthesized the BCR-ABL degrader DAS-6-2-2-6-CRBN containing dasatinib and CRBN ligand, which showed potent degradation of BCR-ABL and growth inhibition in CML cells [171].